AI Faces the Workflow Test
Newly released documents raise questions about Medicare's WISeR pilot after a vendor warned that its launch schedule was unrealistic. STAT also reported care delays during the early rollout. Meanwhile, new AI tools are being introduced for competitive intelligence, nursing, primary care and hospital operations, while Novo Nordisk plans to test Claude in drug discovery. Outside healthcare, OpenAI is testing sponsored AI conversations, and Raspberry AI is connecting creative work across teams.
Medicare's AI Pilot Meets the Paper Trail
What's Happening
Documents obtained through an Electronic Frontier Foundation lawsuit indicate that Medicare's WISeR prior-authorization model had launch problems, STAT reported. One vendor warned CMS that the schedule was unrealistic, and early implementation contributed to care delays. WISeR began in January across six states and runs through 2031; CMS says licensed clinicians make all non-payment recommendations.
Why This News Is Important
The rollout shows what AI governance looks like in practice. Even when an AI model has clear limits, poor implementation can still lead to delays and problems for patients and providers.
What It Could Mean
Pharma access and patient-support teams may face greater pressure to document how AI-assisted coverage workflows affect delays, abandonment and provider burden. Strong implementation evidence, transparent appeals and clear human oversight could become as important to trust as the model's accuracy.
Source: STAT and Centers for Medicare & Medicaid Services
Read more | CMS model details
Competitive Intelligence Gets a Clinical Backbone
What's Happening
AlphaSense introduced Clinical Trial and Drug Data, bringing trial registries, drug labels, patents and U.S., European and Chinese regulatory information into its life-sciences platform. Users can query the material in natural language, trace answers to source records and assign multi-step monitoring, landscaping and benchmarking work to the company's SuperAnalyst agent.
Why This News Is Important
Competitive intelligence is becoming less about searching separate databases and more about maintaining a connected, cited view of markets, pipelines and evidence. That matters across brand planning, launch strategy, Medical Affairs and portfolio decisions.
What It Could Mean
Teams could use these tools to continuously monitor competitor trials, label changes and adjacent indications, then bring important updates into brand and scientific planning. The real test will be whether the AI can summarize that information quickly without missing important details or losing the link to the original source.
Source: AlphaSense
Read more
The Clinical Copilot Reaches Nurses
What's Happening
Oracle made its Clinical AI Agent for nurses available in the United States within the Oracle Health Foundation EHR. The system provides voice-driven chart search, AI-generated acute nursing summaries and voice-enabled structured charting. Oracle says clinicians remain in control; early adopters have discussed potential benefits, but the announcement did not provide independent outcome data for the nursing release.
Why This News Is Important
Clinical AI is widening beyond physicians and ambient notes. Nurses sit at the center of patient education, care coordination and the practical handoffs that determine whether a treatment plan is understood and followed.
What It Could Mean
Better information retrieval and timely documentation could give care teams a more current picture of patient needs and barriers. For pharma, that may eventually support more coordinated education and support services, as long as the summaries remain accurate and reflect the full patient context and organizations continue to measure effects on workload, safety and communication quality.
Source: Oracle
Read more
Primary-Care AI Clears a Higher Bar
What's Happening
Qure.ai said Aira, its AI clinical decision-support system for frontline primary care, received Class IIb certification under the European Union Medical Device Regulation. Aira combines documentation, workflow automation, EHR analysis and guideline-based recommendations. The company reports ten pilot sites across five countries; its deployment and performance figures remain company-reported rather than independent outcome evidence.
Why This News Is Important
The certification treats integrated clinical support as regulated medical software, not a generic chatbot. It also highlights a design priority often overlooked in wealthier markets: local languages, unreliable connectivity and continuous contact between visits.
What It Could Mean
Patient-support and medical-education programs may increasingly need to work alongside regulated AI tools designed for local healthcare settings. That could extend guideline-based communication in underserved settings, but wider adoption should still depend on local validation and evidence that the tool improves patient outcomes.
Source: Qure.ai
Read more
Novo Gives Claude a Scientific Brief
What's Happening
Novo Nordisk and Anthropic announced a collaboration focused on drug discovery and AI-supported software development. Novo will test Claude Science on selected research workflows and scientific problems identified by its teams, while the companies develop targeted tools for biological reasoning. Novo said the work will use data governance, human oversight and its existing compliance standards.
Why This News Is Important
This is not a blanket claim that a frontier model can discover medicines. It is a large pharma company defining specific jobs for a general model, pairing scientific reasoning with the software infrastructure needed to scale it internally.
What It Could Mean
If the tests prove useful, pharma companies may move from using AI for individual tasks to using the same models across more research and technology workflows. The credible near-term opportunity is faster analysis and tool-building; claims about shorter development timelines will require evidence from actual programs.
Source: Novo Nordisk
Read more
Hospitals Get a Three-Day Warning
What's Happening
GE HealthCare launched CareIntellect for Operations, an AI-enabled application designed to forecast hospital capacity constraints up to 72 hours ahead and recommend actions involving discharge, imaging, transfers and staffing. Duke Health and The Queen's Health Systems will be the first clinical evaluation sites. The new product's operational impact has not yet been independently established.
Why This News Is Important
Health systems are starting to use AI not just to understand what has already happened, but to anticipate staffing and capacity problems before they occur. For pharma leaders, hospital capacity is not background infrastructure; it can shape treatment initiation, diagnostics, infusion access and the patient experience around complex therapies.
What It Could Mean
As health systems learn to anticipate bottlenecks, manufacturers may have better opportunities to coordinate support around times when capacity problems could delay care. Over time, operational forecasts could inform patient-support timing and site-of-care planning, though those uses would require appropriate data boundaries and evidence that recommendations improve access.
Source: GE HealthCare
Read more
Primary Care Tests the Next Best Action
What's Happening
Sentara Health will pilot GW RhythmX's AI-supported clinical recommendations with 30 physicians and advanced practice providers across two markets for 90 days. The system brings together patient history, guidelines, care gaps, payer and formulary information, and social and financial factors. Sentara plans to assess adoption, trust, workflow fit and whether recommendations lead to meaningful action.
Why This News Is Important
The pilot goes beyond ambient documentation into point-of-care recommendation. Because the pilot is small and includes a control group, it may provide a more useful look at whether clinicians actually trust and use the recommendations.
What It Could Mean
If clinicians find the recommendations useful, HCP engagement may increasingly occur in an environment where care gaps, formularies and patient context are synthesized during the visit. Pharma teams will need scientific content that is current, well structured and easy for clinical systems to evaluate.
Source: Fierce Healthcare
Read more
Outside the Industry
An Ad Becomes a Conversation
What's Happening
OpenAI began testing Sponsored Agents with selected U.S. advertisers. After clicking an ad in ChatGPT, a user can enter a clearly labeled conversation with a business-sponsored agent, separate from ChatGPT's independent answer. OpenAI also added natural-language campaign management, AI creative assistance, contextual text adaptation and integrations with HubSpot and Shopify.
Why This News Is Important
Advertising is starting to behave less like a message and more like an interactive service. Instead of simply showing someone an ad, brands can now continue the interaction by answering questions in a clearly sponsored conversation.
What It Could Mean
Healthcare marketers should watch the separation between independent answers and sponsored conversation closely. A future regulated version could support approved product education or service navigation, but it would require clear disclosure, approved-content controls, adverse-event handling and clear escalation when a question goes beyond what the sponsored agent is allowed to address.
Source: OpenAI
Read more
Fashion Connects Insight to Commerce
What's Happening
Raspberry AI expanded its fashion platform into an agentic workflow connecting consumer and trend intelligence, design, technical design, merchandising, wholesale, marketing and ecommerce. Teams can guide and review work as concepts become assortments, presentations, campaign creative and product pages. The company's efficiency figures are customer and vendor-reported, not independently established.
Why This News Is Important
What is interesting is how the platform connects consumer insights, product decisions and content creation in one workflow. Creative AI is moving beyond asset generation toward a more connected workflow, so one approved change can carry through to work across different teams and channels.
What It Could Mean
Pharma cannot work this way without review and regulatory controls, but the connected workflow is still worth watching. Modular evidence, claims, design systems and review metadata could eventually help approved changes carry across channels while preserving expert review at each important step.
Source: Raspberry AI
Read more
In Summary
The reported problems with Medicare's WISeR rollout highlight the importance of testing and oversight when introducing AI into healthcare. Many of this week's other developments involve newly launched tools or early pilots, so their impact in everyday practice is still being evaluated. Outside healthcare, OpenAI and Raspberry AI are exploring new ways to use AI in advertising and creative work.